WEGO Surgery Robot

Note: WEGO Surgery Robot is a subsidiary of WEGO Group, focused exclusively on surgical robotics. For orthopedic implants and spine products, see Wego Ortho, WEGO Group’s orthopedic device division listed on the Shanghai STAR Market.

Shandong WEGO Surgery Robot Co., Ltd. achieved a milestone in Chinese medical device history when its MicroHand S laparoscopic surgical robot became the first domestically-developed endoscopic surgical robot to receive NMPA approval in October 2021. Operating as a subsidiary of WEGO Group—one of China’s largest medical device conglomerates founded in 1988—the company invested over a decade in developing core robotic surgery technologies with fully independent intellectual property rights.

Company Overview

WEGO Surgery Robot emerged from WEGO Group’s strategic expansion into high-end medical equipment. The parent company, WEGO Holding Co., Ltd., has grown from a small infusion set manufacturer into a diversified healthcare enterprise with over 80 subsidiaries, more than 30,000 employees, and operations spanning medical devices, pharmaceuticals, and healthcare services. WEGO Group’s medical device arm trades on the Hong Kong Stock Exchange (1066.HK), while its orthopedic division, WEGO Ortho, is listed on the Shanghai Stock Exchange (688161.SH).

The surgery robot division represents WEGO’s entry into the surgical robotics market, directly challenging the long-standing dominance of imported systems like the da Vinci. By developing proprietary technologies in mechanical design, master-slave real-time control, stereoscopic imaging, and system integration, WEGO broke what industry observers described as a 20-year foreign monopoly on laparoscopic surgical robot technology in China.

Core Products

MicroHand S Surgical Robot System

The MicroHand S is a master-slave robotic system designed for minimally invasive laparoscopic surgery. The system consists of three main components: a surgeon console with stereo image viewer and master manipulators, a patient-side cart with multiple robotic arms, and a high-definition 3D visualization system.

Technical specifications include seven degrees of freedom per arm and 540-degree end-effector rotation, replicating the dexterity of human hand movements for precise suturing and knotting. The 3D stereoscopic imaging system employs dual CMOS sensors to provide surgeons with high-resolution visualization of surgical sites.

The system received NMPA approval in October 2021 for general surgery indications including cholecystectomy, inguinal hernia repair, hiatal hernia repair with fundoplication, hepatic cyst fenestration, appendectomy, and sleeve gastrectomy. Clinical trials have since expanded to urology and gynecology applications.

Technology & Innovation

WEGO Surgery Robot holds over 60 national invention patents covering its core technologies. Key innovations include:

• Multi-DOF wire-driven decoupling design: Improves precision maintenance over extended use
• Reconfigurable master manipulator architecture: Enables lighter robotic arms better suited to surgical requirements
• 5G telesurgery capability: The system has completed numerous long-distance remote surgeries, including procedures spanning over 3,000 kilometers between surgical teams in Qingdao and patients in Guizhou province

The 5G remote surgery capability represents a particular strength—the MicroHand system has conducted more remote surgeries than any other robotic platform globally, with published clinical data showing median total delays of approximately 167 milliseconds during 5G-enabled procedures.

Clinical Experience

Clinical validation of the MicroHand system began in 2014 at Xiangya Third Hospital of Central South University, where 103 cases were completed between 2014 and 2019. Registration clinical trials from 2019 to 2020 added 168 procedures across Xiangya Third Hospital and the Affiliated Hospital of Qingdao University.

Comparative studies published in peer-reviewed journals have evaluated MicroHand S against the da Vinci system. Research on total mesorectal excision for rectal cancer found comparable operative times and oncological outcomes, with MicroHand S demonstrating lower total hospital and surgery costs despite requiring longer setup times.

By 2023, the system had been used for dozens of 5G-enabled remote robot-assisted partial nephrectomies, with published data showing 87% of patients at clinical T1 stage, median surgical duration of 67 minutes, and no major intraoperative or postoperative complications.

Market Position

WEGO Surgery Robot targets the secondary hospital market in China, positioning the MicroHand S at approximately half the price of imported da Vinci systems—estimated around RMB 12.5 million compared to RMB 25 million for da Vinci. This pricing strategy, combined with WEGO Group’s existing sales network of 5,000 representatives across Chinese hospitals, supports market penetration in facilities that previously could not afford robotic surgery capabilities.

The company follows an “equipment-consumables-services” business model similar to established players, with long-term revenue expected from surgical instruments, consumables, and value-added services rather than equipment sales alone.

Awards & Recognition

The MicroHand S Surgical Robot System has received international design recognition:

• Red Dot Design Award
• DFA Design for Asia Awards 2022 Merit Award (Product & Industrial Design category)

Key Milestones

• 2014: Clinical research initiated at Xiangya Third Hospital
• 2019-2020: Registration clinical trials completed (168 cases)
• 2020: First 5G ultra-remote surgery completed (3,000+ km)
• 2021-10: NMPA approval received—first domestic laparoscopic surgical robot in China
• 2022: International design awards received
• 2023: Remote partial nephrectomy series published

Frequently Asked Questions

What procedures can MicroHand S perform?

MicroHand S is approved for general surgery procedures including cholecystectomy, hernia repairs, appendectomy, and bariatric surgery. Clinical applications have expanded to include urology (partial nephrectomy) and gynecology procedures.

How does MicroHand S compare to da Vinci?

Published comparative studies show similar operative times and surgical outcomes, with MicroHand S offering lower total costs. The da Vinci system has broader indications and longer clinical history, while MicroHand S provides advantages in 5G telesurgery capabilities and pricing for the Chinese market.

Is WEGO Surgery Robot publicly traded?

WEGO Surgery Robot operates as a subsidiary of WEGO Group. The parent company’s medical device division trades on the Hong Kong Stock Exchange (1066.HK), and the orthopedic division trades on the Shanghai Stock Exchange (688161.SH).